AI Terminal
Biotage
Declaration of Voting Results & Voting Rights Announcements • Jun 30, 2023
2894_rns_2023-06-30_bd5d82ac-7ccb-4178-a342-6aa6123cc4f0.pdf
Declaration of Voting Results & Voting Rights Announcements
Open in ViewerOpens in native device viewer
Change in number of shares and votes
As previously announced, Biotage AB (publ) ("Biotage") has during June 2023 issued 13,954,103 new ordinary shares in connection with the acquisition of Astrea Bioseparations. Prior to the issue, the total number of outstanding shares in Biotage amounted to 66,713,592 and the total number of votes amounted to 66,056,756.7. Through the issue, the number of shares in Biotage has increased by 13,954,103 ordinary shares, corresponding to 13,954,103 votes. As of today, the last trading day of the month, the total number of registered shares in Biotage amounts to 80,667,695, whereof 79,937,878 are ordinary shares and 729,817 are class C shares held by Biotage. As of today, the number of votes in Biotage amounts to 80,010,859.7, and the registered share capital amounts to SEK 112,128,096.05.
About Biotage
Biotage is a Global Impact Tech Company committed to solving society's problems. We offer workflow solutions and products to customers in drug discovery and development and diagnostics, analytical testing and water and environmental testing.
Biotage is contributing to sustainable science with the goal to make the world a healthier, greener and cleaner place – HumanKind Unlimited.
Our customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research and contract manufacturers as well as clinical, forensic and academic laboratories in addition to organizations focused on food safety, clean water and environmental sustainability.
Biotage is headquartered in Uppsala in Sweden and employs around 700 people worldwide. The Group had sales of 1,566 MSEK in 2022 and our products are sold in more than 80 countries. Biotage's share (BIOT) is listed in the Large Cap segment on the NASDAQ Stockholm.
Website: www.biotage.com
Contacts
Tomas Blomquist, President and CEO Tel: 0705 23 01 63, [email protected]
This information is information that Biotage is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-06-30 17:30 CEST.
This information is information that Biotage is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-06-30 17:30 CEST.
